# DT-9081

Source: https://onco.cc/drugs/dt-9081/  
OnCo record `dt-9081` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DT-9081 is an experimental oral small molecule from Domain Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

DT-9081 is an oral small molecule (receptor antagonist) from Domain Therapeutics. An oral EP4 receptor antagonist designed to reverse the immune suppression caused by prostaglandin E2 made by COX-2-positive tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 EPRAD (NCT05582850) terminated at the end of dose escalation, "based on Sponsor's strategic decision"; the company still lists DT-9081 as "Phase II-ready". Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DT-9081
- Modality: Oral small molecule (receptor antagonist)
- Mechanism: An oral EP4 receptor antagonist designed to reverse the immune suppression caused by prostaglandin E2 made by COX-2-positive tumours.

## Sources

- Domain Therapeutics: kainovatx.com: https://www.kainovatx.com/
- Domain Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05582850
- ClinicalTrials.gov: trials of DT-9081: https://clinicaltrials.gov/search?intr=DT-9081

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Kainova Therapeutics](https://onco.cc/companies/domain-therapeutics/)
- trials: [DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours](https://onco.cc/trials/nct05582850/)
- targets: [EP4 (PTGER4)](https://onco.cc/targets/ep4/)

---
JSON: https://onco.cc/api/v1/entities/dt-9081.json